
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is facing short-term sales force inefficiencies and pricing pressures that have caused management to significantly reduce their 2026 outlook for sales growth to 8%, a significant decrease from their previous guidance of 15%. Despite this adjustment, the company's OviTex portfolio is positioned to address various surgical procedures, and a potential increase in healthcare spending could improve their long-term outlook.
Bears say
TELA Bio is facing numerous challenges that are putting pressure on the company's stock. These include a significant slowdown in revenue growth, conservative guidance from management due to strategic overhauls, and a decrease in top-line expectations for the future. The company's concentrated product portfolio and expectations for losses and potential dilution also add uncertainty to its prospects. All of these factors contribute to the negative outlook on this stock.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares